Acetaminophen Toxicity: Experimental and Clinical Advances provides detailed information on the risks of consuming the drug in various situations and effective treatments of toxicity. Divided into two parts, the foundational aspects of the book cover the mechanism of toxicity in a detailed manner, beginning with the history of acetaminophen and then delving into newly explored areas of genetics, proteomics, and metabolomics. The second half discusses clinical practices and examines where further research and therapeutic approaches may be headed. This part answers key questions about who to treat, what are the exceptions, how long do you treat, how much antidote do you need, when are other treatments necessary, and what are those other treatments. With contributions from experts in the field, the book is a thorough, well-researched, and a valuable reference for scientists, researchers, and clinicians engaged in pursuing better and more accurate diagnosis and treatment of patients with of acetaminophen toxicity.
Author Biography:
Dr. Barry H. Rumack, MD is currently Professor Emeritus of Pediatrics and Emergency Medicine at the University of Colorado School of Medicine, Chairman Emeritus, Micromedex, Inc., and Director Emeritus of the Rocky Mountain Poison Center of the Denver Department of Health & Hospitals, University of Colorado Health Sciences Center. His research interests include Acetaminophen Overdose and General Medical Toxicology. He has published over 250 peer-reviewed articles, authored or edited numerous books and book chapters. He is on the editorial board of a number of journals including Clinical Toxicology, Emergency Medicine, among others. He is a Fellow of the American Academy of Clinical Toxicology, American College of Medical Toxicology, and American Academy of Pediatrics and member of Society of Toxicology, American Association of Poison Control Centers, and American College of Emergency Medicine.
Dr. Hartmut Jaeschke, PhD, is the University Distinguished Professor and Chairman of the Department of Pharmacology, Toxicology, and Therapeutics at the University of Kansas Medical Center, Kansas City, Kansas. He joined KUMC in 2006. He is a Fellow of the Academy of Toxicological Sciences and Fellow of the American Association for the Study of Liver Diseases. He has published more than 470 peer-reviewed manuscripts, invited reviews, and book chapters in the areas of liver toxicology and liver pathophysiology. He currently serves as Associate Editor for Toxicological Sciences, the inaugural Editor-in-Chief of Livers (since 2020) and is a member of 14 editorial boards. In 2019, he was the recipient of the Translational Impact Award from the Society of Toxicology. His major research interests include basic mechanisms and translational aspects of xenobiotic-induced hepatotoxicity and tissue repair with a focus on acetaminophen overdose and mechanisms of inflammatory liver injury in animal models and humans. Dr. Mitchell R. McGill is currently an Assistant Professor in the Dept. of Environmental and Occupational Health, at the Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences. He received his PhD at the University of Kansas School of Medicine where he studied toxicology and liver injury biomarkers and pursued his postdoctoral studies in clinical chemistry and liver metabolism at Washington University School of Medicine. Areas of research interests include toxicology, disease biomarkers, and liver pathophysiology. Dr. McGill has over 90 journal publications and numerous book chapters, oral presentations, and meeting abstracts on this the topic of acetaminophen research. He has served as a reviewer and is on the editorial board of Food and Chemical Toxicology, Livers, Toxicological Sciences, and Cells Tissues Organs. He is a member of Society of Toxicology, the American Association for the Study of Liver Diseases, and the American Association for Clinical Chemistry.
